Blood tests for ovarian cancer risk
Raised to date
$5.8M
of $5.8M offered across 3 Form D filings
Aspira Women's Health Inc. is a leading bio-analytical women's health company dedicated to the development of innovative diagnostic tools specifically for gynecologic diseases. With a strong focus on enhancing early detection and risk assessment, particularly for ovarian cancer, Aspira aims to address significant challenges in women's health diagnostics.
What sets Aspira apart is its commitment to improving early detection rates for gynecologic diseases through a combined portfolio of proprietary blood tests and its own CLIA-certified laboratory, enabling reliable and swift results.
| Filed | Security | Sold of offered | Filing |
|---|---|---|---|
| Jun 22, 2026 | Equity | $1.5M/ $1.5M | Form D |
| Sep 18, 2025 | Equity | $3M/ $3M | Form D |
| Mar 20, 2025 | Equity | $1.4M/ $1.4M | Form D |
Diagnostic Blood Tests
OvaSuite is a comprehensive suite of blood tests designed to aid in the assessment of ovarian cancer risk. It includes specific tests tailored to monitor and evaluate the presence of malignancy in adnexal masses.
Built for
Gynecologists and women's health providers
